International prognostic scoring system and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndrome

British Journal of Haematology

Volumn 115, Issue 2, 2001, Pages 309-312

  Kita Sasai, Yuri ^a   Horiike, Shigeo ^a   Misawa, Shinichi ^a   Kaneko, Hiroto ^a   Kobayashi, Miyako ^a   Nakao, Mitsushige ^a   Nakagawa, Hitoshi ^b   Fujii, Hiroshi ^b   Taniwaki, Masafumi ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO FIRST RED CROSS HOSPITAL   (Japan)

Author keywords

Chromosomes; IPSS; Myelodysplastic syndrome; Prognosis; TP53

Indexed keywords

ACCURACY; ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; EVALUATION; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; GENES, P53; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

EID: 0035725856     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2001.03073.x     Document Type: Article

References (10)

1. Proposals for the classification of the myelodysplastic syndromes
2. Application of the international scoring system for myelodysplasia to M.D. Anderson patients
3. International scoring system for evaluating prognosis in myelodysplastic syndromes
4. Chromosome abnormalities and karyotypic evolution in 83 patients with myelodysplastic syndrome and predictive value for prognosis
5. Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes
6. TP53 mutations emerge at early phase of myelodysplastic syndrome and are associated with complex chromosomal abnormalities
7. RAS. FMS and p53 mutations and poor clinical outcome in myelodysplasia: A 10-year follow-up
8. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies
9. Extended cytogenetic follow-up of patients with myelodysplastic syndromes (MDS)
10. Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukaemia